<- Go home

Added to YB: 2026-08-17

Pitch date: 2026-08-13

CPH.TO [neutral]

Cipher Pharmaceuticals Inc.

+1.65%

current return

Author Info

Petty Cash shares microcap investing ideas (mainly in Canada) in their newsletter. Sign up for the newsletter.

Company Info

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients.

Market Cap

CAD 327.5M

Pitch Price

CAD 13.91

Price Target

N/A

Dividend

N/A

EV/EBITDA

11.90

P/E

11.45

EV/Sales

6.42

Sector

Pharmaceuticals

Category

value

Show full summary:
Cipher Pharmaceuticals Q2 2026 Update – CPH.TO

CPH.TO (earnings): Q2 FY26 rev $12.1M (-9.8% YoY), adj EBITDA $6.8M (56.7% margin); stock -21% on weak Natroba (-19% US) from lower Medicaid volumes in seasonally strong qtr. Epuris Canada strong (+14%, 47% share). Walked from large M&A on price/product. 8.6x EV/EBITDA, ~10x FCF. Long, largest holding.

Read full article (4 min)